GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neon Therapeutics Inc (NAS:NTGN) » Definitions » Intrinsic Value: Projected FCF

Neon Therapeutics (Neon Therapeutics) Intrinsic Value: Projected FCF : $0.00 (As of May. 07, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Neon Therapeutics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-07), Neon Therapeutics's Intrinsic Value: Projected FCF is $0.00. The stock price of Neon Therapeutics is $3.07. Therefore, Neon Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Neon Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:

NTGN's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.38
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Neon Therapeutics Intrinsic Value: Projected FCF Historical Data

The historical data trend for Neon Therapeutics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neon Therapeutics Intrinsic Value: Projected FCF Chart

Neon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Intrinsic Value: Projected FCF
- - - -

Neon Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neon Therapeutics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Neon Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neon Therapeutics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neon Therapeutics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Neon Therapeutics's Price-to-Projected-FCF falls into.



Neon Therapeutics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Neon Therapeutics  (NAS:NTGN) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Neon Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3.07/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neon Therapeutics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Neon Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Neon Therapeutics (Neon Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
40 Erie Street, Suite 110, Cambridge, MA, USA, 02139
Neon Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Executives
Cary Pfeffer director C/O ELEVEN BIOTHERAPEUTICS, 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Jolie Siegel officer: VP, General Counsel C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Robert Kamen director C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, BOSTON MA 02210
Meryl Zausner director C/O NEON THERAPEUTICS, INC., 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Yasir B. Al-wakeel officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Eric S Lander director 415 MAIN STREET, CAMBRIDGE MA 02142
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Robert I Tepper director, 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Robert B Bazemore director 33 HAYDEN AVE, LEXINGTON MA 02421
Richard Gaynor officer: President of R&D C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Access Industries, Llc other: Affiliate of 10% Owner 730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Management, Llc other: Affiliate of 10% Owner 730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Clal Biotechnology Industries Ltd. other: See Remarks 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik other: Affiliate of 10% Owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019

Neon Therapeutics (Neon Therapeutics) Headlines

From GuruFocus

Neon Therapeutics Reports Second Quarter 2019 Financial Results

By Marketwired Marketwired 08-06-2019